Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_2
5
56%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(5)
Terminated(3)
Other(1)

Detailed Status

Completed5
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
62.5%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (44.4%)
Phase 25 (55.6%)

Trials by Status

completed556%
terminated333%
unknown111%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_2

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

NCT06447506
terminatedphase_2

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05999799
completedphase_1

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

NCT04975438
completedphase_1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

NCT05590338
completedphase_1

A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease

NCT03681067
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06447506Phase 2

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

Terminated
NCT05999799Phase 2

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Terminated
NCT04975438Phase 1

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Completed
NCT05590338Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

Completed
NCT03681067Phase 1

A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease

Completed
NCT02723786Phase 2

Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation

Terminated
NCT03522662Phase 2

Anti IL-18 (GSK1070806) in Behcet's Disease

Unknown
NCT01035645Phase 1

First Time in Human Study of Intravenous Interleukin-18 Antibody

Completed
NCT01648153Phase 2

Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9